Clinical trials: Atopy, active
Atopic Dermatitis, Atopic
Dietary Intervention on Atopy
Diet is a key determinant of overall health, with growing evidence associating dietary patterns with allergic diseases. Among these, atopic dermatitis (AD) is of particular interest as it often represents the earliest…
- Conditions
- Atopic Dermatitis, Atopic, Allergic Diseases, Allergic Rhinitis
- Trial name
- NCT06547372
- Testing
- Dietary Intervention on Atopy
- Where
- Singapore
- Volunteers
- 110 people
- Sponsor
- National University of Singapore
Atopic Dermatitis
Dupixent and Narrowband UVB for Atopic Dermatitis
24 weeks open-label study with dupilumab and narrowband UVB phototherapy three times weekly for 12 weeks followed by 12 weeks of dupilumab monotherapy.
- Trial name
- NCT05285839
- Testing
- Dupixent
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Psoriasis Treatment Center of Central New Jersey
Atopic Dermatitis, Contact Dermatitis
Methotrexat to Hand Eczema in the BIOSKIN Cohort
Handeczema is a common chronic skin disease that markedly affect health and quality of life. Effective treatment is limited by the lack of biomarkers that can predict disease course, comorbidities and treatment response.
- Conditions
- Atopic Dermatitis, Contact Dermatitis, Hand Eczema
- Trial name
- BIOSKIN: MTX (NCT07338305)
- Where
- Denmark
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Lone Skov
Dermatitis, Contact, Dermatitis
Post-Marketing Clinical Follow-Up Trial to Evaluate the Performance and Safety of the Medical Device 047 TD Dermatitis Cream in Adults and Children With Atopic and Contact Dermatitis Symptoms Confirmed by Clinical Parameters
The study aims to evaluate and confirm the performance of 047 TD Dermatitis cream in the improvement of eczematous dermatitis and contact dermatitis, throughout a reduction in disease severity and symptoms.
- Conditions
- Dermatitis, Contact, Dermatitis, Dermatitis, Chronic, Dermatitis, Eczematous
- Trial name
- NCT07056569
- Testing
- 047_TD Dermatitis cream twice a day for 28 days
- Where
- 3 sites in Italy
- Volunteers
- 90 people
- Sponsor
- Biokosmes Srl
Moderate-to-severe Atopic Dermatitis
A Phase II Study of QLS12010 Capsules in Adults With Moderate to Severe Atopic Dermatitis
This trial was designed to evaluate the efficacy and safety of QLS12010 Capsules in adults with moderate-to-severe atopic dermatitis.
- Trial name
- NCT07344051
- Testing
- QLS12010
- Volunteers
- 160 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Atopic Dermatitis
An Observational Study to Assess Change in Disease Activity and Use of Upadacitinib Tablets in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis in Real World
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. This study will assess how effective upadacitinib is in treating AD. Upadacitinib is an approved drug for treating AD.
- Trial name
- UPDATE (NCT05669794)
- Where
- 59 sites in France
- Volunteers
- 300 people
- Sponsor
- AbbVie
Atopic Dermatitis
A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Moderate to Severe Atopic Dermatitis (AD)
This is a Phase 1, randomized, blinded, placebo controlled, single ascending dose (SAD) study of BBT001 in healthy volunteers (HVs) and adult patients with moderate to severe Atopic Dermatitis (AD).
- Trial name
- NCT07239947
- Testing
- BBT001
- Where
- 10 sites in China
- Volunteers
- 99 people, healthy volunteers welcome
- Sponsor
- Bambusa Therapeutics
Atopic Dermatitis (AD)
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Profiles of TLL-018 in Patients With Moderate-to-Severe Atopic Dermatitis
This is an operationally seamless Phase II/III, multicenter, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe atopic dermatitis (AD).
- Trial name
- NCT07784816
- Testing
- TLL-018 tablets
- Where
- China
- Volunteers
- 390 people
- Sponsor
- Hangzhou Highlightll Pharmaceutical Co., Ltd
Atopic Dermatitis (AD)
A Phase 1/1b Study to Evaluate Safety, Tolerability and Pharmacokinetics of ZL-1503 in Healthy Volunteers and Participants With Moderate to Severe Atopic Dermatitis
This is a phase 1/1b randomized, double blind, placebo-controlled, single dose escalation (SAD) and multiple dose escalation (MAD) study to evaluate the safety, tolerability, and pharmacokinetics (PK) of ZL-1503 in healthy…
- Trial name
- NCT07235384
- Testing
- ZL-1503
- Where
- 12 sites in Australia, China and 1 more
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Zai Lab (Shanghai) Co., Ltd.
Allergy, Respiratory Distress
Primary Allergy and Its Impact on the Occurrence of Respiratory Distress in Infants at 12 Months of Age
The number of people with allergies has been steadily increasing over the years. Symptoms in infants, such as bronchiolitis, gastroesophageal reflux, eczema, or atopic dermatitis, can be early warning signs of allergies in…
- Conditions
- Allergy, Respiratory Distress, Atopic Manifestations, Immediate Postnatal Parameters
- Trial name
- AIRE (NCT07832643)
- Testing
- questionnaire
- Where
- France
- Volunteers
- 508 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Atopic Dermatitis, Psoriasis
Molecular Signatures in Inflammatory Skin Disease
This pilot project intends to examine the utility of a systems medicine approach to identify regulatory networks and their perturbation in psoriasis and atopic dermatitis, and to obtain a comprehensive perspective on disease and…
- Trial name
- MSID (NCT03358693)
- Testing
- Anti-TNF, Anti-IL12/23, Anti-IL17
- Where
- Germany
- Volunteers
- 300 people
- Sponsor
- Prof. Dr. Stephan Weidinger
Atopic Dermatitis
A Study to Observe How Pediatric Patients With Severe Atopic Dermatitis Despite Less Extensive Skin Lesions Respond to Dupilumab Treatment
In adolescents treated with dupilumab, clinical trials showed significant improvement of atopic dermatitis (AD) signs and symptoms, with a good safety profile.
- Trial name
- AD-BEASCUITS (NCT06192563)
- Testing
- Dupilumab
- Where
- 9 sites in Italy
- Volunteers
- 230 people
- Sponsor
- Sanofi
Alopecia Areata
Regeneron AA Multicenter (Dupilumab)
This is a prospective, randomized, double blind, placebo-controlled clinical trial. The study will take place at 4 sites. This trial will enroll a total of 68 patients with moderate to severe AA (affecting more than 50% of the…
- Trial name
- NCT05551793
- Testing
- Dupilumab
- Where
- 3 sites in United States
- Volunteers
- 76 people
- Sponsor
- Emma Guttman
Atopic Dermatitis
A Study to Evaluate the Safety and Tolerability of Multiple Dose of IBI3002 in Patients With Atopic Dermatitis
This study is a randomized, double-blind, placebo-controlled study aimed at evaluating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of multiple doses of IBI3002 in participants with moderate to…
- Trial name
- NCT07015762
- Testing
- IBI3002
- Where
- China
- Volunteers
- 9 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Atopic Dermatitis
A Clinical Study of HRS-8797 in Healthy Participants
The purpose of this phase I study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of HRS-8797 in healthy participants.
- Trial name
- NCT07698756
- Testing
- HRS-8797
- Where
- China
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Chengdu Suncadia Medicine Co., Ltd.
Atopic Dermatitis (AD)
A Study for HSK44459 in Participants With Atopic Dermatitis
The purpose of this study is to assess the efficacy and safety of HSK44459 in adults with Atopic Dermatitis
- Trial name
- NCT06996912
- Testing
- HSK44459
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Xizang Haisco Pharmaceutical Co., Ltd
Atopic Dermatitis
Topical Treatment for Atopic Dermatitis
Medication adherence is a poorly studied phenomenon that challenges both patients and physicians. 50% of individuals with chronic disease are not adherent to their medication regimen.
- Trial name
- NCT06244212
- Testing
- Demonstration of applying triamcinolone cream, Mobile App Use, Standard of Care
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Wake Forest University Health Sciences
Eczema, Atopic Dermatitis
Sodium in the Skin and Atopic Dermatitis
The goal of this observational study is to understand factors associated with skin sodium storage in healthy adults and people with atopic dermatitis ages 50 and above.
- Trial name
- SIS-AD (NCT06998446)
- Where
- 2 sites in United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Atopic Dermatitis (AD), Autoantibody
Birth Cohort: Development of IgE Autoantibodies in Newborns With (High Risk of) Atopic Dermatitis
Previous research has shown that some patients with atopic eczema have specific self-reactive antibodies, known as IgE autoantibodies, that react to their own skin cells, referred to as "self-reactive antibodies" or…
- Conditions
- Atopic Dermatitis (AD), Autoantibody, Auto-Immunity, Microbiome, Human
- Trial name
- DIANA (NCT07316465)
- Testing
- Development of atopic dermatitis with/without IgE autoantibodies
- Where
- Belgium
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Universitair Ziekenhuis Brussel
Atopic Dermatitis
A Study Evaluating APG777 in Atopic Dermatitis
This is a two-part study that will evaluate the safety and efficacy of APG777 in participants with moderate-to-severe Atopic Dermatitis (AD).
- Trial name
- NCT06395948
- Testing
- APG777
- Where
- 94 sites in United States, Canada and 7 more
- Volunteers
- 470 people
- Sponsor
- Apogee Therapeutics, Inc.